The Tampa Division

DEA Tampa Field Division and Its Diversion-Control System

Last fully verified: July 25, 2026

Executive Finding

The Drug Enforcement Administration is currently operating a Tampa Field Division under Special Agent in Charge Daniel Escobar.

Its exact jurisdiction, office network, public contact structure, and date of establishment are not clearly disclosed.

DEA’s live Tampa Division page contains only the word “Florida,” lists Tampa as its sole contact location, and leaves the fields for its main telephone number, media inquiries, recruitment, and street address blank. At the same time, DEA’s separate live Miami Division page continues to say that Miami is “Serving Florida” and continues to list Jacksonville, Orlando, Tampa, and West Palm Beach as Miami Division contacts.

Current DEA press releases nevertheless establish that Tampa is functioning as a separate field division. Those releases identify Daniel Escobar as its Special Agent in Charge and show Tampa Division operations extending through:

Tampa and the surrounding region
Orlando and Central Florida
Jacksonville and Northeast Florida
Tallahassee
Pensacola
The Florida Panhandle
Other North Florida communities

A May 2026 Florida news report described the Tampa Field Division as “newly formed,” but no official DEA establishment announcement, reorganization order, effective date, county map, or comprehensive office-transfer notice was located during this review.

The most defensible conclusion is:

The Tampa Field Division is a newly operational DEA regional command with demonstrated responsibility across North and Central Florida. The Miami Division remains an active command in South Florida. DEA’s current public materials do not establish the exact county-level boundary between them or identify which former Miami offices and personnel have formally transferred to Tampa.

The incompleteness extends to leadership records.

DEA’s current press releases repeatedly identify Daniel Escobar as Tampa’s Special Agent in Charge. DEA’s national leadership directory, however, lists a heading for the Tampa Division without naming a leader or providing a biography. The same directory identifies Miles D. Aley as Miami’s Special Agent in Charge.

Some current Tampa Division press releases contain an additional contradiction: the body identifies Daniel Escobar as Tampa SAC, while the footer still identifies Miles D. Aley as “Special Agent in Charge – Miami” and links to Miami Division social media. The media number used on those Tampa releases is also the number published on the Miami Division page.

This appears to be incomplete website and communications migration. That is an inference. DEA has not publicly explained the discrepancy.

The division’s diversion-control structure is even less visible.

DEA does not currently publish:

The Tampa Division’s senior diversion official
Its Diversion Program Manager
Diversion group supervisors
The location of its Diversion Investigators
The counties assigned to each diversion group
Its registration-assistance structure
Its inspection workload
Its administrative-action totals
Its registration-processing times
Its continuity-of-care measurements
The division of diversion authority between Tampa and Miami

The public record therefore establishes that the Tampa Division exists and exercises federal authority. It does not yet provide the information required to map or evaluate the complete institution.

Who the Tampa Division Serves

The Tampa Field Division serves communities and DEA registrants within an incompletely defined portion of Florida.

Current official case materials establish Tampa Division activity in both the Middle District of Florida and the Northern District of Florida, including matters arising in Orlando, Jacksonville, Highlands County, Tallahassee, Pensacola, Okaloosa County, and other Panhandle communities.

Its regional responsibilities may affect:

Physicians
Dentists
Advanced practice registered nurses
Physician assistants
Pharmacies
Hospitals
Veterinarians
Researchers
Manufacturers
Distributors
Narcotic treatment programs
Institutional practitioners
Other DEA registrants
Patients whose treatment depends on those registrants

Florida is one state, but it is not one uniform healthcare market.

The apparent Tampa territory contains:

Major metropolitan regions
Large retirement populations
Rural inland communities
Coastal communities
Military communities
Agricultural regions
University and research centers
Panhandle counties separated from Tampa by substantial distance
Areas with sharply different levels of physician, pharmacy, and hospital access

The same federal Controlled Substances Act applies throughout the region. Its practical consequences may differ significantly according to geography.

The 2026 Jurisdictional Reorganization

What DEA’s Tampa Page States

DEA’s live Tampa page displays:

“Tampa Division”
“Florida”
A standard office-type legend
Blank contact fields
No street address
One contact entry labeled “Tampa”
No telephone number beside that entry

The word “Florida” does not establish whether Tampa serves:

The entire state
North and Central Florida
A particular collection of counties
One or more federal judicial districts
A temporary transition territory

It is insufficient to define the division’s jurisdiction.

What DEA’s Miami Page States

DEA’s separate live Miami page continues to state:

Serving Florida

It also publishes the following locations as Miami Contacts:

Location	Telephone
Jacksonville	904-348-5225
Orlando	407-333-7000
Tampa	813-287-5160
West Palm Beach	561-684-8000

The page identifies Miles D. Aley as Miami’s Special Agent in Charge.

This page appears to preserve the former statewide Miami structure—or at least substantial parts of it—even though DEA is now publicly issuing releases under a separate Tampa Field Division.

What Current Tampa Releases Establish

Current DEA releases identify Daniel Escobar as Tampa SAC in matters arising in:

Pensacola
Mary Esther
Tallahassee
Marianna
Fort Walton Beach
Crestview
Panama City
Highlands County
Orlando and Central Florida

The releases use language referring to the Florida Panhandle and “North Florida communities.”

That record establishes operational reach.

It does not establish an exact county boundary.

What Can Be Concluded

The evidence supports the following conclusions:

A separate Tampa Field Division is operating.
Daniel Escobar is functioning as its Special Agent in Charge.
The Tampa Division exercises authority in North Florida.
It exercises authority in the Florida Panhandle.
It exercises authority in at least portions of Central Florida.
DEA continues to operate a separate Miami Division under Miles D. Aley.
The Miami website has not been fully reconciled with the Tampa reorganization.
The Tampa website has not been fully populated.

What Cannot Be Concluded

The current public materials do not establish:

The exact date the Tampa Division was created
The legal or administrative instrument creating it
The complete list of counties transferred from Miami
The exact Tampa–Miami boundary
Whether any counties remain jointly administered during transition
Whether the boundary follows federal judicial districts
Whether enforcement, diversion, intelligence, and registration operations use identical boundaries
Which offices formally report to Daniel Escobar
Whether West Palm Beach remains with Miami
Whether Fort Myers belongs to Tampa or Miami
Whether Jacksonville and Orlando have formally transferred
How registrant files and pending investigations were reassigned
How legacy Miami Division cases are attributed after the reorganization

Seeds of Vice does not resolve these questions by assumption.

The absence of an official boundary map is itself an institutional finding.

Territory and Office Structure

Tampa Division Headquarters

DEA’s current Tampa page identifies Tampa as the division location but publishes no:

Headquarters address
Main telephone number
Media email
Recruitment contact
Diversion contact
Community-outreach contact

DEA’s live Miami page still publishes the following telephone number beside Tampa:

813-287-5160

That is a current DEA-published number.

The website does not clearly state whether it is now:

The Tampa Division headquarters number
A subordinate office number
A legacy Miami Division number
A number awaiting reassignment
A current number displayed under an outdated division heading

It should therefore be described precisely as:

Live DEA-published Tampa office number appearing on the Miami Division page; current division-level status not separately confirmed.

Jacksonville

DEA’s live Miami page continues to list:

904-348-5225

Current 2026 DEA investigations in Jacksonville fall within the operational record now associated with Daniel Escobar and the Tampa Field Division, but the Tampa page does not list Jacksonville as an office.

The available record does not establish whether Jacksonville is formally classified as a:

District office
Resident office
Post of duty
Other subordinate location

Orlando

DEA’s live Miami page continues to list:

407-333-7000

Current federal diversion matters identify DEA’s Orlando offices and Daniel Escobar as Tampa Division SAC. An April 2026 veterinary matter also published the email address OrlandoDiversion@dea.gov for diversion tips and complaints.

This establishes an operating DEA presence in Orlando.

It does not establish the office’s current formal classification or complete staffing structure.

West Palm Beach

DEA’s Miami page lists:

561-684-8000

No official source reviewed for this page established that West Palm Beach transferred to Tampa.

It should not be placed under the Tampa Division without further evidence.

Northern Florida and the Panhandle

Current Tampa Division releases establish activity in:

Tallahassee
Pensacola
Panama City
Marianna
Crestview
Fort Walton Beach
Mary Esther
Perry
Sopchoppy

The releases do not provide a complete office directory or identify which of those cities contain permanent DEA offices.

A case location is not automatically an office location.

Seeds of Vice does not convert prosecution venues into DEA offices.

Office Classifications

DEA’s Tampa page displays a legend containing:

Division Office
District Office
Resident Office
Post of Duty Office

It does not assign those classifications to a complete list of locations.

No classification has been inferred from:

Telephone numbers
City size
Federal judicial districts
Historical Miami Division records
The presence of a local investigation
Media-release datelines

Current Leadership and Publicly Identified Personnel

Daniel Escobar

Special Agent in Charge

Current official DEA press releases repeatedly identify Daniel Escobar as Special Agent in Charge of the Tampa Field Division.

That identification appears in releases involving North Florida, the Panhandle, Central Florida, and diversion-control matters in Orlando.

Accordingly, Daniel Escobar should be treated as the current Tampa SAC.

Missing Official Biography

DEA’s national leadership directory contains a Tampa Division heading but does not publish:

Escobar’s name
His photograph
His biography
An appointment date
His prior assignments
His education
His previous diversion-control experience
The date he assumed command

No separate official DEA appointment announcement or biography was located during this review.

Seeds of Vice therefore does not invent or reconstruct his career from unofficial professional profiles.

“Newly Formed” Status

A May 2026 WPTV/Scripps report described Escobar as the Special Agent in Charge of DEA’s “newly formed Tampa Field Division.”

That description is credible corroboration that the division was recently established.

It is not a substitute for an official creation order.

The exact formation date remains unverified.

Miles D. Aley

Special Agent in Charge, Miami Division

DEA’s leadership directory and Miami page identify Miles D. Aley as the current Miami SAC.

Aley should not be presented as the Tampa SAC.

However, current Tampa press-release pages still display him in their footer as “Special Agent in Charge – Miami.”

The most reasonable interpretation is that DEA’s press-release templates or division tags have not been fully migrated.

That conclusion is an inference, not an official explanation.

Publicly Unidentified Diversion Leadership

DEA does not currently publish the name of the Tampa Division’s:

Diversion Program Manager
Senior diversion official
Assistant Special Agent in Charge responsible for diversion
Diversion group supervisors
Registration supervisor
Tactical Diversion Squad supervisors
State or regional diversion coordinators
Diversion public-affairs representative

DEA also does not disclose:

How many Diversion Investigators report to Tampa
Which offices contain Diversion Investigators
Whether Miami and Tampa temporarily share diversion personnel
How pending regulatory cases were divided
Which division administers registrations in disputed or transitional counties
Whether separate Tampa registration email addresses have been established

The absence of publicly named personnel does not prove that the positions are vacant.

It means the command structure is not publicly visible.

The Name Matters

The Tampa Field Division is not the national Diversion Control Division.

The Tampa Field Division is a regional DEA command that performs or supervises:

Criminal enforcement
Intelligence
Administration
Community engagement
Diversion-related work

The national Diversion Control Division administers major portions of DEA’s nationwide regulatory program governing controlled pharmaceuticals and listed chemicals.

DEA describes the national diversion mission as preventing controlled pharmaceuticals and listed chemicals from being redirected from legitimate sources while also preserving an adequate and uninterrupted supply for legitimate medical, scientific, and commercial needs.

The accurate title for this page is therefore:

DEA Tampa Field Division and Its Diversion-Control System

It should not be described as a separate “Tampa Diversion Division.”

Official Role and Mission

Diversion control has two inseparable institutional obligations.

Preventing Diversion

DEA is responsible for addressing controlled substances that leave lawful channels through conduct such as:

Theft
Forged prescriptions
Falsified records
Employee diversion
Unlawful prescribing
Improper dispensing
Registration misuse
Inventory concealment
Suspicious distribution
Failure to report significant losses
Diversion from hospitals or veterinary facilities

Preserving Legitimate Supply

DEA’s mission also expressly recognizes the need for an adequate and uninterrupted supply for:

Medical use
Scientific use
Commercial use

That obligation reaches:

Surgery
Emergency medicine
Cancer treatment
Palliative care
Hospice
Anesthesia
Acute-pain treatment
Chronic-pain treatment
Mental-health treatment
Addiction treatment
Veterinary medicine
Research
Pharmaceutical manufacturing and distribution

A complete evaluation of the Tampa Division cannot measure only drugs seized, registrations surrendered, civil penalties, or convictions.

It must also examine whether legitimate medicine remained available.

The Closed System of Distribution

The federal controlled-substance system regulates the movement of controlled drugs through lawful channels.

Depending on the activity, participants may include:

Manufacturers
Distributors
Importers
Exporters
Pharmacies
Hospitals
Clinics
Physicians
Dentists
Veterinarians
Researchers
Narcotic treatment programs
Mid-level practitioners
Other institutional and individual registrants

DEA registration generally authorizes specific activities involving specific schedules of controlled substances.

Registration does not replace state authority.

A Florida practitioner may require:

A valid professional license
State prescribing authority
DEA registration
Institutional credentialing
Compliance with Florida prescribing law
Compliance with E-FORCSE
Compliance with employer or hospital policy
Compliance with insurer or pharmacy requirements

A person may therefore possess state licensure but lack federal authority—or possess federal registration but lack the required state authority for a particular activity.

Traditional Regional Diversion Work

The Tampa Division’s diversion-control functions may include:

Reviewing registration matters
Conducting regulatory inspections
Auditing inventories
Examining purchasing records
Examining dispensing records
Investigating thefts and significant losses
Investigating forged prescriptions
Investigating unlawful prescribing
Investigating employee diversion
Examining institutional security
Reviewing automated dispensing records
Investigating registration-number misuse
Coordinating with Florida licensing boards
Coordinating with E-FORCSE
Negotiating corrective agreements
Seeking civil penalties
Accepting or requesting registration surrender
Recommending administrative proceedings
Referring evidence for criminal prosecution

Not every inspection produces enforcement.

Not every recordkeeping defect is criminal.

Not every settlement proves every allegation.

Not every surrender is a criminal conviction.

The legal posture of each matter must be preserved.

Broader Enforcement Is Not Diversion Control

The Tampa Division also investigates:

Illicit fentanyl
Methamphetamine
Cocaine
Heroin
Counterfeit tablets
Drug-trafficking organizations
Firearms associated with trafficking
Money laundering
Interstate and transnational distribution

Current Tampa releases from Pensacola, Tallahassee, Highlands County, and other North Florida locations establish the division’s enforcement footprint. They do not establish the size or performance of its diversion-control program.

For example:

A fentanyl seizure does not reveal how many pharmacies were inspected.
A methamphetamine prosecution does not show registration-processing times.
A trafficking conviction does not establish whether lawful medicine remained available.
A North Florida arrest does not identify the division’s county boundary.
A criminal case does not reveal how many registrants were found compliant.

Illicit-market enforcement and lawful-channel regulation can intersect.

They are not the same dataset.

Florida’s State Regulatory Layer

E-FORCSE

Florida’s Prescription Drug Monitoring Program is known as E-FORCSE, the Electronic-Florida Online Reporting of Controlled Substance Evaluation Program.

Florida states that the program was created by the 2009 Legislature to encourage safer controlled-substance prescribing and reduce abuse and diversion. Dispensers submit controlled-substance information, and authorized prescribers may consult patient dispensing histories.

E-FORCSE is a Florida state system.

It is not a database created or exclusively controlled by the Tampa Field Division.

Reporting Requirements

Florida requires dispensers to report covered Schedule II, III, IV, and V controlled substances as soon as possible and generally no later than the close of business on the day after dispensing.

The reporting requirement applies to covered pharmacies, pharmacists, and dispensing practitioners.

Consultation Requirements

Florida states that prescribers or their designees generally must consult E-FORCSE before prescribing Schedule II through V controlled substances to patients age sixteen or older.

Published exceptions include:

The patient is younger than sixteen
The prescription is for a nonopioid Schedule V drug
The system is officially unavailable
A temporary technological or electrical failure prevents access

Florida also requires dispensers to consult the system in covered circumstances, including subsequent refills of Schedule III, IV, and V prescriptions. If a dispenser cannot consult the system, Florida requires documentation of the reason and generally limits dispensing to a three-day supply.

Penalties and Data Retention

Florida states that an initial failure to consult may result in a non-disciplinary citation, while subsequent failures may result in professional discipline under the applicable licensing board’s guidelines.

E-FORCSE information more than four years old is purged.

This retention limit is important when evaluating historical prescribing patterns. The live operational database is not itself a complete permanent record extending back to 1984.

Federal and State Authority

The existence of E-FORCSE does not transfer Florida’s professional-licensing authority to DEA.

Likewise, DEA registration authority does not eliminate state requirements.

A practitioner may simultaneously answer to:

DEA
Florida Department of Health
A professional licensing board
E-FORCSE requirements
Hospitals
Insurers
Pharmacies
Employers
Federal or state prosecutors

When prescribing changes, responsibility may therefore be divided among several institutions.

How the System Works in Practice

Prescribers

Federal controlled-substance prescriptions must be issued for a legitimate medical purpose by an authorized practitioner acting in the usual course of professional practice.

Florida law adds state-specific licensing, monitoring, documentation, and prescribing requirements.

A practitioner may also be affected by:

Hospital policy
Insurer limitations
Pharmacy refusals
Corporate risk rules
Dosage thresholds
Documentation expectations
Fear of investigation
Fear of professional discipline
Supply-chain limitations

A decline in prescribing does not independently reveal which institution caused it.

Pharmacists

Pharmacists have independent legal and professional responsibilities.

They may evaluate:

Prescription validity
Practitioner authority
Refill timing
Quantity
Dosage
Drug combinations
Patient identification
Geographic distance
Payment method
Possible forgery
Other warning signs

A pharmacist may decline to dispense even when the prescriber considers the medication appropriate.

The refusal may arise from:

Law
Professional judgment
E-FORCSE information
Employer policy
Insurer requirements
Inventory limitations
Distributor restrictions
Concern about regulatory exposure

The public record seldom identifies which factor controlled an individual refusal.

Hospitals

Hospitals and clinics may be expected to monitor:

Controlled-substance inventories
Employee access
Automated dispensing cabinets
Override activity
Wastage
Discrepancies
Missing medication
Altered records
Delayed reports
Suspected employee impairment

Hospital diversion can directly harm patients when medication is removed, diluted, substituted, or unavailable.

Veterinarians

Veterinary practitioners and facilities remain part of the controlled-substance system.

Their obligations may include:

Secure storage
Accurate inventories
Administration records
Dispensing logs
Employee-access controls
Theft reporting
Disposal
Registration compliance

The fact that the patient is an animal does not remove the drug from federal regulation.

Diversion Control and Lawful Medicine

The need for diversion control is real.

The Tampa regional record includes allegations or admissions involving:

Fraudulent prescriptions
Improper dispensing
Missing records
Prescribing without legitimate medical purpose
Inadequate veterinary inventories
Registration surrender

The need for lawful treatment is also real.

A registration action can affect:

Patients
Employees
Hospitals
Pharmacies
Rural communities
Other practitioners asked to assume care
Emergency departments
Family caregivers

The available public record does not establish whether the Tampa Division systematically measures:

The number of patients affected by an enforcement action
Whether patients receive advance notice
Whether medical records are transferred
Whether another prescriber is available
Whether a pharmacy remains open
Whether rural patients must travel farther
Whether cancer, hospice, surgical, addiction-treatment, or pain patients lose continuity
Whether abrupt discontinuation occurs
Whether lawful supply remains adequate following an intervention

The absence of published measurements does not prove that no internal safeguards exist.

It establishes that the public cannot evaluate them.

Prescribing Statistics Without False Continuity

Seeds of Vice uses 1984 as the historical starting point for examining the transformation of lawful medicine.

That does not mean one comparable annual dataset runs from 1984 through the present.

It does not.

No defensible source located for this page provides a continuous, annual, same-definition Florida opioid-dispensing series beginning in 1984 and extending through 2026.

The Tampa Division itself did not exist as a publicly identified separate field division throughout that period.

Accordingly:

Missing years are not interpolated.
Statewide Florida data are not assigned solely to Tampa.
Prescription counts are not treated as dosage measurements.
Prescriptions per 100 residents are not treated as MME per capita.
E-FORCSE totals are not merged directly with CDC retail estimates.
Patient counts are not treated as prescription counts.
Overdose deaths are not treated as prescribing rates.
Miami-era data are not automatically attributed retrospectively to Tampa.
Different datasets are not joined into a false line.

1984–2005

For this period, the defensible record must be assembled from separate sources involving:

Federal controlled-substance policy
DEA registration history
National pharmaceutical distribution
Medical practice
State law
Drug-utilization studies
Later retrospective research

Those materials can document historical conditions.

They do not provide a continuous Tampa Division prescription rate.

Seeds of Vice does not invent annual values for missing years.

2011 State Benchmark

CDC’s archived retail-pharmacy estimate reported that Florida dispensed:

83.5 opioid prescriptions per 100 residents in 2011.

That was a statewide estimate.

It was not a Tampa Division statistic.

At the time, Florida was publicly administered through the Miami Field Division structure rather than the separate Tampa Division now operating.

The 2011 figure does not reveal:

The number of individual patients
Average dosage
Duration of treatment
Diagnosis
Medical appropriateness
Diversion
Adequacy of treatment
Geographic distribution within Florida
Whether a later decline resulted from DEA
Whether state law, licensing boards, pharmacies, insurers, hospitals, or clinical practice caused the change

A dispensing rate measures volume under a specific methodology.

It does not decide the legitimacy of individual treatment.

Florida’s 2025 PDMP Measures

Florida Health CHARTS reports the following statewide 2025 measures derived from the state Prescription Drug Monitoring Program:

Measure	2025 statewide total or rate
Opioid prescriptions dispensed	11,088,081
Unique patients receiving an opioid prescription	2,939,220
Unique opioid prescribers	87,779
Opioid prescriptions per patient	3.8
Opioid prescriptions per prescriber	126.3

Florida explains that these measures are organized by the dispenser’s county. Its annual unique-patient and unique-prescriber totals avoid repeatedly counting the same person across quarters.

The same dashboard reports for 2025:

5,253,798 stimulant prescriptions
7,999,650 benzodiazepine prescriptions
98,711 muscle-relaxant prescriptions

These figures are valuable state context.

They are not Tampa Division performance statistics.

They cannot be divided between Tampa and Miami without a verified county boundary and the underlying county-level allocation.

They also should not be directly compared with the CDC’s 2011 prescriptions-per-100-residents estimate as though the measures were identical.

Current National Retail Series

CDC reports that the national retail opioid-dispensing rate declined from:

46.8 prescriptions per 100 persons in 2019
To 35.4 prescriptions per 100 persons in 2024

That is a decline of approximately 24.4 percent.

CDC describes these as retail-pharmacy dispensing estimates and notes substantial variation among states and counties. The agency also states that prescription opioids continue to contribute to opioid-related deaths but are not the primary current driver of the national overdose crisis.

These figures do not measure:

All hospital administration
All institutional use
All treatment-program dispensing
Every prescription channel
Individual medical necessity
Patient-reported pain
Treatment adequacy
Diversion
The effect of one regional DEA division

What the Prescribing Record Establishes

The defensible conclusion is limited:

Lawful retail opioid dispensing has declined substantially from the elevated levels documented during the early twenty-first century.

The record does not independently prove:

Why every decline occurred
Whether DEA caused it
Whether Miami-era or Tampa-era operations caused it
Whether every reduction represented better care
Whether every discontinued prescription was unnecessary
Whether diversion declined proportionately
Whether pain prevalence declined
Whether undertreatment increased
Whether pharmacy barriers increased
Whether clinicians became more accurate
Whether clinicians became more fearful
Whether patients retained adequate treatment

Population-level volume cannot decide the medical justice of an individual case.

Representative Diversion-Control Matters

These matters illustrate diversion-control activity within the region now publicly associated with the Tampa Division.

They are not a complete list, a random sample, or a division-wide performance measure.

Orlando Pharmacy and Pharmacist

Civil settlement of allegations

On July 9, 2026, Plaza Pharmacy LLC and pharmacist Paul Ezeobinwa agreed to pay $50,000 to resolve federal Controlled Substances Act allegations.

The government alleged that, between December 2021 and March 2024, the pharmacy failed to identify 104 fraudulent prescriptions with 193 refills, resulting in Schedule V medication being dispensed without valid prescriptions. DEA’s on-site investigation also identified dozens of alleged recordkeeping violations.

The pharmacy surrendered its DEA registration for cause in May 2024 and ceased operating in September 2025. Daniel Escobar was quoted in his capacity as Tampa Field Division SAC. DOJ expressly stated that the resolved claims remained allegations and that there had been no determination of liability.

This was:

A civil settlement
A resolution of allegations
Not a criminal conviction
Not a finding that every allegation was proven at trial

The matter demonstrates regional diversion work involving:

Fraudulent prescriptions
Pharmacy dispensing
Recordkeeping
On-site inspection
Registration surrender
Civil resolution

Jacksonville Nurse Practitioner

Guilty plea

On June 1, 2026, Jacksonville nurse practitioner Kenyatta Dacres pleaded guilty to unlawful distribution of controlled substances.

According to DOJ, Dacres prescribed an undercover DEA agent increasing amounts of hydrocodone even after he stated that he was not experiencing pain. She also prescribed amphetamine despite the absence of a supporting diagnosis and despite information concerning a recent methamphetamine arrest. A reviewing physician concluded that the prescriptions lacked a legitimate medical purpose and were issued outside the usual course of professional practice.

At the time of the announcement, sentencing had not yet been scheduled.

This was:

A guilty plea
Not merely an allegation
Not yet a completed sentencing record as of the cited announcement

The matter demonstrates:

Undercover investigation
Mid-level practitioner authority
Prescription legitimacy review
Opioid and stimulant prescribing
Criminal enforcement

East Volusia Veterinary Facility

Pending civil allegations

On April 21, 2026, the United States filed an eleven-count civil action against veterinarian Dr. Kerri Zavota and the Veterinary Emergency Center of East Volusia.

The government alleged failures to track and document controlled substances, including fentanyl. According to the complaint announcement, an employee contacted DEA’s Orlando offices, investigators responded, and the government alleged hundreds of violations involving blank or inconsistent dispensing logs and inventories.

DOJ expressly stated that the claims were allegations and that no liability determination had been made.

This was:

A filed civil lawsuit
Not a settlement
Not a guilty plea
Not a conviction
Not a final liability judgment

The matter demonstrates:

Employee reporting
Veterinary controlled substances
Fentanyl accountability
Inventory requirements
Dispensing logs
Civil enforcement

What the Representative Matters Show

The matters establish that regional diversion can involve:

Fraudulent prescriptions
Prescribing without legitimate medical purpose
Pharmacy recordkeeping
Veterinary inventories
Registration surrender
Civil litigation
Criminal prosecution

They do not establish how frequently those events occur among all Tampa-region registrants.

Press releases do not reveal:

The total number of registrants
The number inspected
The number found compliant
The number receiving technical assistance
The number of complaints found unsupported
The number of cases closed without action
The number receiving warning letters
The number entering corrective agreements
The number contesting administrative action
The number prevailing
The number of patients affected
Average investigation length
Average registration-processing time

A group of announced cases establishes that enforcement occurred.

It does not describe the complete regulatory system.

Legal Posture Must Be Preserved

The following terms are not interchangeable.

Allegation

The government asserts that conduct occurred.

Civil complaint

The government files claims in court. Liability has not been determined.

Indictment or criminal charge

A defendant is formally accused and remains presumed innocent unless proven guilty.

Guilty plea

A defendant admits guilt in court.

Conviction

Guilt is established through plea or verdict.

Sentence

A court imposes punishment after conviction.

Civil settlement

The parties resolve civil claims, often without obtaining a judicial finding on every allegation.

Administrative action

DEA acts against a registration through the administrative system.

Voluntary or agreed surrender

A registrant relinquishes federal authority. A surrender may occur under pressure or as part of an agreement but is not automatically a criminal conviction.

Dismissal or acquittal

Claims or charges are dismissed, or the accused is found not guilty.

Seeds of Vice preserves these distinctions in both directions.

Government allegations should not be minimized.

They also should not be upgraded into findings that were never made.

Practical Consequences for Registrants

A Tampa Division registration or compliance matter may result in:

No action
Education
Technical correction
Follow-up inspection
Additional documentation
Corrective-action requirements
A memorandum of agreement
Civil penalties
Restrictions on schedules or activities
Registration surrender
An order to show cause
Immediate suspension
Revocation
Criminal referral
Criminal prosecution

DEA does not publish Tampa-level totals for these outcomes.

The public therefore cannot determine whether the program operates primarily through:

Education
Correction
Negotiation
Restriction
Punitive enforcement
Criminal referral

The most serious cases are more likely to receive publicity.

Routine compliance work remains comparatively invisible.

Practical Consequences for Patients

Patients are ordinarily not the formal subjects of DEA registration enforcement.

They may nevertheless experience its effects.

Legitimate Benefits

Diversion action may:

Stop fraudulent prescriptions
Detect stolen medication
Identify unlawful prescribing
Correct pharmacy deficiencies
Improve hospital controls
Protect animal patients
Remove impaired personnel from drug access
Prevent pharmaceuticals from reaching illicit markets

Possible Adverse Consequences

An action may also contribute to:

Loss of a prescriber
Clinic closure
Pharmacy closure
Delayed refills
Pharmacy refusal
Longer travel
Difficulty transferring records
Abrupt treatment interruption
Greater emergency-department use
Reduced willingness among clinicians to accept complex patients
Loss of treatment in rural communities

The existence of those possible consequences does not establish that every action causes patient harm.

It establishes why patient effects should be measured.

Geographic Consequences

A regulatory action in metropolitan Tampa or Orlando may leave several nearby treatment alternatives.

An equivalent action in:

The Panhandle
Rural North Florida
Inland agricultural counties
Smaller Gulf Coast communities
Communities with few specialists

may produce substantially different access consequences.

Equal legal standards do not always produce equal practical effects.

That is a geographic inference.

It is not an allegation that the Tampa Division deliberately applies different standards to rural communities.

Public Contact Information

Tampa Division Page

As of July 25, 2026, the live Tampa Division page publishes no:

Main telephone number
Media contact
Recruitment contact
Diversion contact
Headquarters address

Tampa Office Number Published on Miami Page

813-287-5160

This number remains listed under the live Miami Division’s Tampa contact entry. DEA has not clearly relabeled it as the Tampa Division headquarters line.

Current Media Number Used on Tampa Releases

(571) 362-3364 — Option 5

Current Tampa Division press releases use this number. It is also the media number published on the Miami Division page.

The shared number may reflect temporary or continuing communications support from Miami. DEA does not publicly explain the arrangement.

Orlando Diversion Tips and Complaints

OrlandoDiversion@dea.gov

DOJ published this address in April 2026 for reports concerning possible diversion, abuse, or controlled-substance mismanagement.

This should not automatically be treated as the registration-help address for the entire Tampa Division.

National DEA Registration Support

Telephone: 1-800-882-9539
Email: DEA.Registration.Help@dea.gov
Published service hours: 8:30 a.m.–5:50 p.m. Eastern Time

Because the Tampa–Miami transition is not clearly documented, registrants should verify which regional office currently handles their county and matter rather than relying solely on older Miami assignments.

Seeds of Vice Analysis

The following is Seeds of Vice analysis.

It is not an official DEA statement.

The Tampa Division’s Defining Feature Is Institutional Transition

Tampa is not merely a division with an incomplete webpage.

The public record shows a federal command already exercising authority while the agency’s public infrastructure remains divided between the old and new arrangements.

DEA currently presents:

A Tampa page without contacts
A Miami page still claiming Florida
Miami contacts that include Tampa, Orlando, and Jacksonville
Current releases naming Daniel Escobar as Tampa SAC
A leadership directory that omits Escobar
Tampa releases carrying a Miami SAC footer
Tampa releases using Miami’s media telephone number

Each item may be explained as website migration.

Together, they show an incomplete public reorganization.

DEA Has Not Published the Foundational Document

The most important missing record is not a biography or telephone number.

It is the document explaining what the Tampa Division is.

The public should be able to determine:

When it was created
Why it was created
Which counties it serves
Which offices transferred
Which personnel transferred
Which registrations transferred
Which investigations transferred
Where Miami responsibility ends
Where Tampa responsibility begins

Without that information, the public cannot reliably identify the proper regional command.

The Jurisdictional Gap Has Practical Consequences

An unclear boundary can affect:

Registrants seeking application assistance
Pharmacies reporting losses
Hospitals reporting employee diversion
Attorneys identifying the relevant office
Journalists seeking public information
Patients attempting to understand an action
State officials coordinating with DEA
Members of the public submitting tips
Researchers assigning cases to a field division

A jurisdictional map is not decorative.

It is basic administrative accountability.

The Leadership Record Is Internally Contradictory

Current official press releases leave little doubt that Daniel Escobar commands Tampa.

The national leadership directory’s omission should therefore not be treated as evidence that the position is vacant.

At the same time, the absence of:

An official biography
An appointment announcement
An assumption-of-command date
An organizational statement

prevents meaningful public evaluation of the division’s first publicly identified leader.

A new federal field division should not begin its public life through scattered quotations in criminal-case announcements.

Diversion Structure Is Almost Entirely Invisible

The Orlando pharmacy case proves that Tampa has Diversion Investigators.

The Orlando veterinary case proves that an Orlando diversion contact exists.

Those isolated facts do not reveal the system.

The public still cannot determine:

Who leads Tampa diversion operations
Whether separate groups serve Jacksonville, Orlando, Tampa, and the Panhandle
Whether Miami continues to process registrations for some Tampa counties
How files were divided
Whether personnel shortages exist
How inspections are prioritized
How long applications remain pending

That is a substantial transparency deficit.

Reorganization Complicates Historical Attribution

Most Florida data predating 2026 were generated while Miami was the publicly identified statewide field division.

Those data cannot simply be relabeled as Tampa history.

Likewise, a case investigated before the reorganization but announced afterward may involve:

Miami-era personnel
Tampa-era leadership
A transferred case file
Shared resources
A newly assigned press-release label

The institution should explain how it attributes inherited investigations.

Seeds of Vice should not guess.

Statewide Florida Statistics Are Not Tampa Statistics

Florida’s PDMP data describe the state.

The Tampa Division serves an undefined part of that state.

Until DEA publishes a verified county map, statewide totals cannot be divided responsibly between Tampa and Miami.

A state prescribing decline also does not independently measure DEA performance.

The decline may reflect:

State legislation
E-FORCSE
Licensing-board action
Insurer rules
Pharmacy policies
Distributor controls
Clinical guidance
Hospital policy
Practitioner judgment
Federal enforcement
Changing patient populations

The relevant institutions should not be collapsed into one causal claim.

Enforcement Announcements Show Cases, Not Institutional Balance

The Tampa regional record includes legitimate examples of:

Fraudulent prescriptions
Unlawful prescribing
Pharmacy deficiencies
Veterinary recordkeeping concerns

Those matters demonstrate why diversion oversight exists.

They do not establish:

The proportion of registrants who comply
The proportion corrected informally
The proportion punished
The number of unsupported complaints
The number of patients affected
Whether lawful access remained adequate
Whether the division uses proportionate remedies

Public accountability requires denominators.

Lawful Access Must Be Measured

DEA’s national diversion mission already includes preserving adequate and uninterrupted legitimate supply.

A new field division has an opportunity to build that obligation into its public reporting from the beginning.

It should measure:

Registrations processed
Inspections conducted
Violations corrected
Enforcement actions taken
Patients potentially displaced
Alternate treatment capacity
Rural access
Record-transfer arrangements
Continuity following clinic or pharmacy action

A system that counts registrations removed but not patients displaced measures only one side of its own mission.

The Central Question

The central question is not whether the Tampa Division has authority.

It does.

The question is whether the division can define itself publicly with the same precision it expects from the registrants it regulates.

A regulated pharmacy must know:

Who owns it
Where it operates
What authority it holds
Which records it must maintain
Who is responsible

The federal division regulating that pharmacy should meet a comparable institutional standard.

Recommended Public Disclosures

Seeds of Vice recommends that DEA publish a formal Tampa Field Division establishment and transition report.

Creation and Jurisdiction

DEA should disclose:

The official creation date
The administrative authority establishing the division
The effective operational date
The reason for the reorganization
The exact counties assigned to Tampa
The counties retained by Miami
A county-level jurisdiction map
Whether enforcement and diversion boundaries are identical
Procedures for cross-boundary matters
Procedures for cases initiated before the transfer

Office Network

DEA should identify:

Tampa headquarters address
Main telephone number
Jacksonville office status
Orlando office status
Tallahassee office status
Pensacola office status
Other North Florida locations
Any Central or Southwest Florida locations
Office classification for every location
Which offices contain diversion personnel
Which offices accept public inquiries
Which offices process registration matters

Leadership

DEA should publish:

Daniel Escobar’s official biography
Appointment date
Prior assignments
Command responsibilities
Named Deputy Special Agent in Charge
Named Assistant Special Agents in Charge
Current diversion leadership
Public-affairs contacts
Community-outreach contacts
Recruitment contacts

Diversion Structure

DEA should disclose:

Current Diversion Program Manager
Diversion organizational chart
Supervisory groups
County assignments
Number of Diversion Investigators
Office placement
Vacancies
Registration specialists
Public contact routes
Whether Miami temporarily supports Tampa

Registration Transition

DEA should explain:

How active registrant files were transferred
How pending applications were reassigned
Whether registration numbers changed
Whether applicants must resubmit documents
Which email address registrants should use
How processing delays are measured
How mistakenly routed inquiries are handled
Whether Miami and Tampa share a transition queue

Regulatory Workload

An annual report should include:

Active registrants by category
New applications
Renewals
Modifications
Denials
Withdrawals
Average processing time
Pending cases
Inspections
Registrants found compliant
Technical deficiencies
Corrective actions
Follow-up inspections
Matters closed without enforcement

Enforcement

DEA should separately report:

Administrative subpoenas
Inspection warrants
Search warrants
Warning letters
Memoranda of agreement
Civil penalties
Civil settlements
Voluntary surrenders
Orders to show cause
Immediate suspension orders
Restrictions
Revocations
Criminal referrals
Charges
Guilty pleas
Convictions
Acquittals
Dismissals
Government withdrawals

Theft and Loss

DEA should disclose:

Reports received
Registrant types involved
Substances and quantities
Employee-diversion matters
Outside thefts and burglaries
Reporting delays
Average investigation time
Corrective actions
Matters determined not to involve registrant misconduct

E-FORCSE and Data Use

DEA should explain, without revealing protected techniques:

How Tampa obtains E-FORCSE information
What legal process is required
Who authorizes requests
How access is audited
How inaccurate data are corrected
How four-year data purging affects investigations
How prescribing volume is distinguished from evidence of illegality
How information is transferred between Tampa and Miami

Patient and Community Effects

DEA should measure:

Patients potentially affected by registration action
Advance-notice procedures
Medical-record transfer
Alternate-provider availability
Pharmacy continuity
Hospital continuity
Addiction-treatment continuity
Cancer and hospice considerations
Rural and Panhandle access
Complaints involving abrupt discontinuation
Whether adequate lawful supply remained available

These disclosures can be aggregated and anonymized.

They do not require disclosure of active investigative techniques or private patient records.

Methodology and Evidentiary Limits

This page was fully reviewed through July 25, 2026.

Priority was given to:

DEA
DEA Diversion Control
United States Department of Justice
Centers for Disease Control and Prevention
Florida Department of Health
Florida Health CHARTS
Current official case announcements

A reputable Florida news report was used only to corroborate the public description of Tampa as a newly formed division. It was not used to invent an establishment date or jurisdictional boundary.

The following rules were applied:

Daniel Escobar is identified as current SAC because multiple current official DEA releases name him in that capacity.
The omission of his name from DEA’s leadership directory is preserved as a conflicting official record.
Miles D. Aley is identified as Miami SAC, not Tampa SAC.
The Miami footer appearing on Tampa releases is preserved as a website inconsistency.
No official creation date is invented.
No county boundary is inferred.
No office is transferred from Miami to Tampa without evidence.
Case locations are not treated as office locations.
Office classifications are not inferred.
The Tampa Field Division is distinguished from the national Diversion Control Division.
Illicit-market enforcement is separated from diversion-control work.
Allegations, civil complaints, settlements, guilty pleas, convictions, sentences, administrative actions, and registration surrenders are treated as different legal events.
Press releases are treated as selected case records, not comprehensive statistics.
Statewide Florida data are not presented as Tampa Division data.
Miami-era activity is not automatically relabeled as Tampa history.
CDC estimates and Florida PDMP totals are not merged into one continuous series.
Prescription counts, patient counts, prescriptions per 100 residents, MME measurements, overdose deaths, and seizures are not treated as interchangeable.
Missing years beginning in 1984 are not interpolated.
No causal conclusion is drawn merely because prescribing, enforcement, and overdose trends overlap.
Possible patient effects are described as possible consequences or reasoned inferences unless direct evidence establishes them.
Seeds of Vice analysis is separated from the official record.

The public record establishes that the Tampa Field Division is real, active, and led by Daniel Escobar.

It does not yet establish its precise territorial boundaries, complete office network, formal creation history, current diversion chain of command, registration-transition procedures, or the measures by which the public can evaluate whether it is protecting lawful medicine while preventing diversion.